Loading provider…
Loading provider…
Hematology & Oncology Physician in Milwaukee, WI
NPI: 1386668192Primary Practice Location
FROEDTERT MEMORIAL LUTHERAN HOSPITAL
900 N 92nd St, Milwaukee, WI
Primary Employer
The Medical College of Wisconsin, Inc.
mcw.edu
HQ Phone
Get M.D. John's Phone Numberphone_androidMobile
Get M.D. John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWI State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 61 | 89 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 50 | 144 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 25 | 72 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 25 | 42 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 17 | 57 |
Authors: David King, Adam Wooldridge, John Neilson, Candice Johnstone, Tracy Kelly, Donald Hackbarth
Journal: Adv Radiat Oncol
Publication Date: 2022-01-25
Authors: Mohammed Milhem, Varun Monga, Angela Hirbe, Brian Schulte, Nisha Mohindra, Steven Robinson, Scott Okuno, Mark Agulnik, Peter Oppelt
Journal: Br J Cancer
Publication Date: 2021-05-28
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Temozolomide, OTHER: Quality-of-Life Assessment, DRUG: Cabozantinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, PROCEDURE: Computed Tomography, DRUG: Cabozantinib S-malate, PROCEDURE: FDG-Positron Emission Tomography
Lead Sponsor: Adaptimmune
Collaborators: ICON plc
Intervention / Treatment: GENETIC: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks